R
Robert S. Fishman
Publications - 7
Citations - 607
Robert S. Fishman is an academic researcher. The author has contributed to research in topics: Pirfenidone & Idiopathic pulmonary fibrosis. The author has an hindex of 4, co-authored 6 publications receiving 484 citations.
Papers
More filters
Journal ArticleDOI
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Paul W. Noble,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Roland M. du Bois,Elizabeth A. Fagan,Robert S. Fishman,Ian Glaspole,Marilyn K. Glassberg,Lisa Lancaster,David J. Lederer,Jonathan A. Leff,Steven D. Nathan,Carlos Alberto de Castro Pereira,Jeffrey J. Swigris,Dominique Valeyre,Talmadge E. King +16 more
TL;DR: Analysis of data from three phase 3 trials demonstrated that treatment with pirfenidone for 1 year resulted in clinically meaningful reductions in disease progression in patients with IPF.
Journal ArticleDOI
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Steven D. Nathan,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Roland M. du Bois,Elizabeth A. Fagan,Robert S. Fishman,Ian Glaspole,Marilyn K. Glassberg,Kenneth F. Glasscock,Talmadge E. King,Lisa Lancaster,David J. Lederer,Z Lin,Carlos Alberto de Castro Pereira,Jeffrey J. Swigris,Dominique Valeyre,Paul W. Noble,Athol U. Wells +18 more
TL;DR: Longitudinal FVC data from patients with IPF showed substantial intrasubject variability, underscoring the inability to reliably assess therapeutic response using serial FVC trends.
Journal ArticleDOI
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
Lisa Lancaster,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Roland M. du Bois,Elizabeth A. Fagan,Robert S. Fishman,Ian Glaspole,Marilyn K. Glassberg,Talmadge E. King,David J. Lederer,Z Lin,Steven D. Nathan,Carlos Alberto de Castro Pereira,Jeffrey J. Swigris,Dominique Valeyre,Paul W. Noble +16 more
TL;DR: A comprehensive analysis of safety outcomes in a large and well-defined cohort of 1299 patients with IPF who were followed prospectively for up to 9.9 years demonstrated that long-term treatment with pirfenidone is safe and generally well tolerated.
Journal ArticleDOI
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials
Ulrich Costabel,Lisa Lancaster,C Albera,Williamson Z. Bradford,Elizabeth A. Fagan,Robert S. Fishman,I Glaspole,Marilyn K. Glassberg,Te King,David J. Lederer,Z Lin,Steven D. Nathan,Carlos Alberto de Castro Pereira,Jeffrey J. Swigris,Dominique Valeyre,Paul W. Noble +15 more
Long-term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF): Integrated Analysis of Data from 4 Clinical Trials
Steven D. Nathan,C Albera,Williamson Z. Bradford,Costabel U,Roland M. du Bois,Elizabeth A. Fagan,Robert S. Fishman,I Glaspole,Marilyn K. Glassberg,Talmadge E. King,Lisa Lancaster,David J. Lederer,Jonathan A. Leff,Carlos Alberto de Castro Pereira,Steven A. Sahn,Jeffrey J. Swigris,Paul W. Noble,Dominique Valeyre +17 more
TL;DR: A comprehensive analysis of safety outcomes among IPF patients receiving pirfenidone for up to 8.6 years demonstrates that long-term treatment was safe and generally well tolerated.